CD33 CAR-T / Alaunos Therap, Precigen, UT MD Anderson Cancer Center - LARVOL DELTA

[VIRTUAL] A Phase 1/1b Safety Study of Prgn-3006 Ultracar-T™ in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndrome (ASH 2020) - P1 | "Superior efficacy of UltraCAR-T cells was demonstrated in an aggressive murine xenograft model of AML where a single administration of PRGN-3006, only one day after gene transfer, showed significantly higher expansion and persistence; effectively eliminated tumor burden; and significantly improved overall survival compared to traditional CD33 CAR-T cells lacking mbIL15 expression (Blood (2019) 134(S1): 2660)...Key inclusion criteria include an absolute lymphocyte count ≥ 0.2k/µL, KPS > 60%, absence of other active malignancy within 1 year of study entry, daily corticosteroid dose < 10mg of prednisone daily, adequate organ function and a backup allogeneic donor should bone marrow aplasia occur. Hydroxyurea is allowed for cytoreduction with cessation 3 days prior to apheresis/infusion but can be reinitiated post-infusion. To test the hypothesis that expression of mbIL15 on PRGN-3006 cells is sufficient to promote CAR-T cell expansion and persistence, study..."

Clinical • IO biomarker • P1 data • Acute Myelogenous Leukemia • Aplastic Anemia • Chronic Myelomonocytic Leukemia • Gene Therapies • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Myelodysplastic Syndrome • Oncology • Transplantation • CD33 • IL15

Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia. (PubMed, Leukemia) - No abstract available

CAR T-Cell Therapy • Journal • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • CD33

Chimeric antigen receptor T-cell therapy for B-cell malignancies: Initiation of P1 trial in H2 2018 (Ziopharm) - Q4 FY2017 Results

New P1 trial • Oncology

Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia (clinicaltrials.gov) - P1; N=11; Completed; Sponsor: M.D. Anderson Cancer Center; Active, not recruiting ➔ Completed; Trial completion date: Aug 2021 ➔ Oct 2019; Trial primary completion date: Aug 2021 ➔ Oct 2019

Clinical • Trial completion • Trial completion date • Trial primary completion date

Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia (clinicaltrials.gov) - P1; N=11; Terminated; Sponsor: M.D. Anderson Cancer Center; Completed ➔ Terminated; Terminated per the PI's request.

Clinical • Trial termination

Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia (clinicaltrials.gov) - P1; N=11; Active, not recruiting; Sponsor: M.D. Anderson Cancer Center; Recruiting ➔ Active, not recruiting

Enrollment closed